Proceedings of the 2nd International Symposium on Business Corporation and Development in South-East and South Asia under B&R Initiative (ISBCD 2017)

Analysis of Exposure to Foreign Exchange Risk for U.S. Pharmaceutical Industry

Authors
Shuting Niu
Corresponding Author
Shuting Niu
Available Online October 2017.
DOI
https://doi.org/10.2991/isbcd-17.2017.45How to use a DOI?
Keywords
Pharmaceutical industry; foreign operations; exposure to foreign exchange risk; risk management
Abstract
Multinational companies with a large proportion of foreign operations face one same problem which is foreign exchange risk. As for the world's largest economy, the United States has various kinds of industries that have global business and trade with currencies of different countries. American pharmaceutical industry is a very typical one, and I choose five sample firms (Merck, AbbVie, Pfizer, Bristol Myers and GSK) with comparably large size, healthy financial status and a lot of international business to analyze the exposure to foreign exchange risk and discuss the management of the risk and finally come up with my own recommendations.
Open Access
This is an open access article distributed under the CC BY-NC license.

Download article (PDF)

Cite this article

TY  - CONF
AU  - Shuting Niu
PY  - 2017/10
DA  - 2017/10
TI  - Analysis of Exposure to Foreign Exchange Risk for U.S. Pharmaceutical Industry
BT  - 2nd International Symposium on Business Corporation and Development in South-East and South Asia under B&R Initiative (ISBCD 2017)
PB  - Atlantis Press
SP  - 220
EP  - 225
SN  - 2352-5428
UR  - https://doi.org/10.2991/isbcd-17.2017.45
DO  - https://doi.org/10.2991/isbcd-17.2017.45
ID  - Niu2017/10
ER  -